Physician · Scientist · Oncologist

Dr. Luciano Mutti

Professor of Oncology · MD, PhD

Physician-scientist, oncologist and international leader in malignant mesothelioma research

Thoracic oncology · Translational cancer research

Portrait · 01
Black-and-white portrait of Dr. Luciano Mutti, oncologist and mesothelioma researcher, wearing a shirt and tie
Dr. Luciano Mutti
“We are deluged by misleading online hype, oftentimes not justified by the factual data. This goes in the very opposite direction we should take to plug the gap of knowledge.”
Luciano Mutti · Newswise · circa January 2022 · Sbarro Health Research Organization (SHRO) independent-research conference announcement
Explore the work
Genoa · University of GenoaSalford · University of SalfordL’Aquila · San Salvatore HospitalRome · UniCamillusPhiladelphia · Temple UniversityItaly · GIMe

Key takeaways

At a glance

  • Born in Genoa, Luciano Mutti is a physician-scientist and oncologist whose work has focused on malignant mesothelioma for more than 30 years.1
  • Mutti is Professor of Oncology at UniCamillus in Rome.1
  • Mutti is Adjunct Professor of Translational Cancer Research at Temple University’s Sbarro Institute.2
  • Mutti is Senior Associate of the Italian National Research Council (CNR).
  • Mutti is President of the Italian Group for Mesothelioma and Environmental Oncology (GIMe).3
  • Since August 2026, Mutti has served as a compensated independent medical reviewer for WikiMesothelioma.4

Career overview

For more than three decades, the professor has worked where laboratory discovery meets patient care—studying mesothelioma’s immune biology, molecular vulnerabilities, resistance mechanisms and the strength of the evidence behind its treatments.

Research philosophy

What discovery requires

Editorial framingRigor is not separate from access. Independent evidence, adequate funding and patient selection shape which discoveries can become meaningful treatment.

“Unfortunately low incidence of mesothelioma means less financial incentive for drug companies, and lower funding for the research.”
Luciano Mutti · Newswise · circa January 2022

The p53-model precision-medicine study, reported in the Journal of Translational Medicine (October 2018) and the International Journal of Molecular Sciences (January 2019):

“This study offers a good approach to test the real impact of genetic studies in precision medicine… we believe it will have a potential for use in Mesothelioma treatment by identifying patient sub-populations that are likely to respond to particular drugs.”
Luciano Mutti · Newswise · circa late 2018 / early 2019
01

The through-line

Four moments in a continuing inquiry

From the immunologic behavior of mesothelioma cells to the fragility of trial evidence: a research record defined by questions that move between bench and bedside

1998

The immune conversation

Early work established that mesothelioma cells can present antigens—part of the immunologic basis for understanding the disease.

2019

A molecular vulnerability

Research connected BAP1 status with gemcitabine sensitivity, advancing a biomarker-driven view of treatment response.

2020

Promise, tested

A critical review of immunotherapy trials separated clinical promise from demonstrated patient benefit.

2022

Evidence under scrutiny

A comparative-effectiveness study re-analyzed three pivotal trials: MPS (2003), MAPS (2016) and CheckMate 743 (2021), examining the statistical fragility of their findings in a JAMA Network Open SHRO/GIMe analysis.

“For all three studies analyzed, there is not really evidence to conclude that any of them improve [malignant pleural mesothelioma (MPM)] patients’ survival.”
Luciano Mutti · Newswise · circa March 2022 · “New Mesothelioma Drugs, Once Hailed as Gamechangers, Don’t Live Up to the Hype”
“how much can we trust the results of large sponsored clinical trials, when the benefit obtained is minimal…”
Luciano Mutti · Newswise · circa March 2022 · same release · excerpt shortened with ellipsis

Research highlights

Selected publications, directly linked

Five selected publications spanning immune biology, molecular signalling, clinical investigation, guideline development and critical appraisal of evidence.

  1. Immune biology

    Antigen presentation by malignant mesothelioma cells

    A preclinical study of malignant mesothelioma cells and the molecules associated with antigen presentation.

    Read on PubMed
  2. VEGF signalling

    VEGF as an autocrine growth factor

    Preclinical research examining VEGF, Flt-1 and KDR signalling in human malignant pleural mesothelioma.

    Read on PubMed
  3. Immunotherapy

    Tremelimumab in malignant mesothelioma

    A phase 2 study of tremelimumab for advanced malignant mesothelioma after platinum-based first-line treatment.

    Read on PubMed
  4. Clinical guidelines

    ERS, ESTS, EACTS & ESTRO guidelines update

    A multidisciplinary guideline update covering diagnosis, pathology, staging, prognosis and treatment of malignant pleural mesothelioma.

    Read on PubMed
  5. Evidence appraisal

    Three frontline mesothelioma trials compared

    A comparative-effectiveness study re-examining MPS, MAPS and CheckMate743 survival evidence.

    Read on PubMed

Earlier diagnosis

On microRNAs, biomarkers and the possibility of finding mesothelioma sooner.

“We hope that the identification of these microRNAs and their mechanisms of action will lead to the identification of biomarkers that could help us to diagnose mesothelioma at an earlier stage and to identify new urgently needed therapeutic strategies.”
Luciano Mutti · News-Medical · September 24, 2020
02

Chronology

A career across disciplines and borders

Clinical medicine, translational research and teaching have remained connected throughout

His career spans Italy, Ireland, England and the United States, connecting clinical oncology with exacting translational research.

  1. University of Genoa

    Genoa, Italy

    MD with honours

  2. Respiratory medicine · Oncology

    Genoa · Turin, Italy

    Specialist qualifications and oncology PhD program

  3. Clinical medicine · Thoracic oncology

    Vercelli, Italy

    General medicine and translational research

  4. Consultant appointments

    Ireland · England

    Clinical oncology

  5. University of Salford

    Salford, England

    Chair in Cancer Research

  6. University of L’Aquila · San Salvatore Hospital

    L’Aquila, Italy

    Professor of Oncology and head of oncology; retired from the Italian public university and Italian National Health Service (SSN) in November 2025

  7. Head of the Regional Cancer Network

    L’Aquila, Italy

    Professor of Oncology

  8. UniCamillus

    Rome, Italy

    Professor of Oncology

  9. The impact of post-progression censoring in second-line immunotherapy studies for mesothelioma

    Journal of Translational Medicine · 21 September 2026

    As corresponding author, with affiliations at UniCamillus and GIMe, Mutti reports a re-analysis of the CONFIRM and PROMISE-meso trials that found the early CONFIRM overall-survival signal coincided with short follow-up and post-progression censoring patterns, with no OS benefit in the longer-follow-up data.

Career chronology: UniCamillus faculty profile

03

Current roles

Teaching, leadership, research and medical review

Turin · Current

Senior Associate

Italian National Research Council (CNR)

L’Aquila · From 2023

Head of the Regional Cancer Network

Professor of Oncology, L’Aquila

04

WikiMesothelioma

Independent medical review

A defined role in making clinical information clearer, more accurate and more useful to readers

Clinical scrutiny, independent of the publisher

Dr. Mutti has served as a compensated independent medical reviewer for WikiMesothelioma since August 2026.

He reviews clinical articles for medical accuracy only. The role does not imply endorsement of WikiMesothelioma, its publisher or any legal service.

05

GIMe

Independent research, centered on patients

An Italian organization bringing research, clinical work and patient protection together in mesothelioma and environmental oncology

GIMe

Gruppo Italiano Mesotelioma e Oncologia AmbientaleItalian Group for Mesothelioma and Environmental Oncology

Visit GIMe

GIMe is an independent, non-profit Italian association for mesothelioma and environmental oncology. Professor Mutti is its President, and his leadership of the organization spans more than a decade.

“For more than twenty years, G.I.Me. has protected patients and their families through independent research that puts the fight against the disease first.”
Luciano Mutti · President’s letter on GIMe · translated from Italian
“Safeguarding our independence has brought together a group of people with diverse scientific expertise who share ideals before knowledge.”
“Far from fads and publicity, we strive to let our scientific output speak for itself.”
  • Patient supportGIMe offers legal support to patients and families. Its website is in Italian and lists an email contact for English-speaking inquiries.
  • National accessIts new office in Voghera is easily reached from across Italy and is staffed monthly.
  • Clinical studiesThe Australian adenosine-inhibitor study with ADDRI Sydney and Professor Kao is delayed for administrative reasons. A Phase Ia/b study of TT-4 is currently ongoing in the United States at Baylor (ClinicalTrials.gov NCT04969315).
  • Research reachGIMe presented at three AACR congresses in one year, including new results on targeted biological therapies.
  • Research standardAt the XVII Weinman Symposium in Hawaii, Mutti’s talk—introduced by 2011 Nobel Medicine laureate Professor Bruce Beutler—argued that new therapies must rest on solid laboratory research conducted with rigor and intellectual honesty.
  • Environmental oncologyTaranto prosecutors asked Professor Mutti, identified by GIMe as its President and a leading oncology figure, for a technical report on benzene and environmental cancer risk.

Recognition

Awards & recognition

As listed in Dr. Mutti’s institutional curriculum vitae, with verified records linked below.

  • “Fair Play” Award for Scientific Research

    Listed in Dr. Mutti’s institutional curriculum vitae as a “Fair Play” Award for Scientific Research connected with Italy’s Olympic National Committee (CONI). The Italian National Fair Play Committee’s “Fair Play for Life” honours recognise figures whose careers embody fair play in science, sport and civic life; its ceremonies have been held in CONI’s Hall of Honour in Rome. Read 2019 Fair Play Day coverage

  • Italian National Award for Research on Asbestos-Related Tumours

    Listed in Dr. Mutti’s institutional curriculum vitae as awarded by the “Italian National Association for Labour” — the CV’s rendering of INAIL, Italy’s National Institute for Insurance against Accidents at Work. INAIL is Italy’s workers’ compensation and occupational-health authority and operates ReNaM, the National Mesothelioma Register. About INAIL

  • AACR Prize

    Dr. Mutti’s institutional curriculum vitae lists him as “Winner AACR Prize, ACCR Kyoto, Japan”. At the AACR Annual Meeting 2025 in Chicago (April 25–30, 2025) — the world’s largest cancer research meeting — he presented Abstract 2247 on suppressing adenosine production combined with PD-1 checkpoint inhibition for malignant pleural mesothelioma. Read the AACR-published abstract · About the AACR Annual Meeting 2025

06

Medical articles

Research, guidelines and evidence

  1. 1998

    Antigen presentation by malignant mesothelioma cells

    International Journal of Cancer · PMID 9833768

    This preclinical in vitro study examined four primary cultures of human malignant mesothelioma cells. The cells expressed antigen-presentation-associated molecules and, after pulsing with recall antigens, induced proliferation of autologous lymphocytes; PPD-pulsed cells stimulated a PPD-specific CD4+ T-cell clone through an MHCII-DR-mediated process.

  2. 2001

    VEGF as an autocrine growth factor

    Journal of Pathology · PMID 11276005 · preclinical research that provided the rationale for chemotherapy plus antiangiogenic therapy, now front-line treatment in many countries

    In this preclinical study of human malignant pleural mesothelioma, cell lines, biopsies and patient effusions were analysed for VEGF signalling. Mesothelioma cells expressed VEGF, Flt-1 and KDR; recombinant VEGF increased proliferation in vitro and neutralising antibodies reduced it, while higher serum VEGF levels were associated with shorter patient survival.

  3. 2010

    ERS/ESTS guidelines on malignant pleural mesothelioma

    European Respiratory Journal · PMID 19717482

    This ERS/ESTS Task Force practice guideline synthesised expert guidance for managing malignant pleural mesothelioma, covering diagnosis, staging, prognosis and therapeutic strategies. It highlighted limitations in diagnostic staining and staging validation, and noted limited evidence on optimal multimodal treatment and the need for prospective study.

  4. 2013

    Tremelimumab in malignant mesothelioma

    The Lancet Oncology · PMID 24035405 · co-last author · the first immune checkpoint inhibitor trial in mesothelioma

    This open-label, single-arm phase 2 trial enrolled 29 patients with unresectable advanced malignant mesothelioma progressing after platinum-based first-line treatment, who received tremelimumab every 90 days. Two patients (7%) had durable partial responses and 31% achieved disease control; the prespecified 17% objective-response target was not met.

  5. 2017

    Anti-CTLA-4 therapy for malignant mesothelioma

    Immunotherapy · PMID 28231719 · co-last author

    This special report reviews clinical trials of tremelimumab in unresectable malignant mesothelioma, addressing clinical efficacy, safety and tolerability. It concludes that biological and clinical considerations did not support tremelimumab monotherapy, and that evidence for immune checkpoint inhibitors in mesothelioma remained limited and uncertain.

  6. 2020

    ERS/ESTS/EACTS/ESTRO guidelines update

    European Respiratory Journal · PMID 32451346

    This multidisciplinary practice guideline updated the 2009 ERS/ESTS recommendations for malignant pleural mesothelioma through a systematic review of 2009–2018 evidence, appraised with GRADE. It addressed diagnosis, pathology, staging, prognostic assessment and treatment, noting limited efficacy of (chemo)therapy, restricted suitability for radical surgery, and limited data on optimal multimodal treatment.

  7. 2022

    Three frontline mesothelioma trials compared

    JAMA Network Open · PMID 35262715

    This comparative effectiveness study examined MPS, MAPS and CheckMate743, three phase 3 frontline randomised trials in malignant pleural mesothelioma. Reconstructed survival analyses found no statistically significant difference between the MAPS and CheckMate743 intervention groups and identified low survival-inferred fragility indices and differential censoring in CheckMate743, factors that may affect interpretation of the original results.

For his full publication record, visit Google Scholar.

PubMed bibliography

Selected PubMed publications

Fourteen curated PubMed records from 1998–2024. Every entry preserves the indexed publication title and links directly to its PMID and DOI; this is a focused bibliography, not a complete author inventory. Updated October 17, 2026.

Sort chronologicallyChronological order: oldest first.
Filter by medical themeShowing all 14 publications.

  1. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes.

    Int J Cancer · PMID 9833768 · DOI 10.1002/(sici)1097-0215(19981209)78:6<740::aid-ijc12>3.0.co;2-5

    Tumour biology

  2. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma.

    J Pathol · PMID 11276005 · DOI 10.1002/path.824

    Tumour biology

  3. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.

    Thorax · PMID 17311837 · DOI 10.1136/thx.2006.069872

    Treatment strategies

  4. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.

    Eur Respir J · PMID 19717482 · DOI 10.1183/09031936.00063109

    Clinical guidance

  5. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

    Lancet Oncol · PMID 24035405 · DOI 10.1016/S1470-2045(13)70381-4

    Immunotherapy

  6. Anti-CTLA-4 therapy for malignant mesothelioma.

    Immunotherapy · PMID 28231719 · DOI 10.2217/imt-2016-0123

    Immunotherapy

  7. Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

    J Thorac Oncol · PMID 29966799 · DOI 10.1016/j.jtho.2018.06.011

    Treatment strategies

  8. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.

    Transl Lung Cancer Res · PMID 32206576 · DOI 10.21037/tlcr.2019.11.23

    Immunotherapy

  9. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.

    Eur Respir J · PMID 32451346 · DOI 10.1183/13993003.00953-2019

    Clinical guidance

  10. Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma.

    JAMA Netw Open · PMID 35262715 · DOI 10.1001/jamanetworkopen.2022.1490

    Evidence appraisal

  11. Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.

    J Thorac Oncol · PMID 35462085 · DOI 10.1016/j.jtho.2022.03.014

    Clinical guidance

  12. Abemaciclib for malignant pleural mesothelioma.

    Lancet Oncol · PMID 35654054 · DOI 10.1016/S1470-2045(22)00276-5

    Treatment strategies

  13. Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology.

    J Transl Med · PMID 36514092 · DOI 10.1186/s12967-022-03744-6

    Evidence appraisal

  14. Based on the Real-World Results From Australia, Immunotherapy Is Not a Good Option for Patients With Mesothelioma.

    J Thorac Oncol · PMID 38582546 · DOI 10.1016/j.jtho.2024.01.016

    Immunotherapy

For broader discovery of the author record, use the PubMed author search.

07

Reviewed articles appendix

Articles reviewed by Dr. Mutti

Twenty-one WikiMesothelioma articles directly reviewed by Dr. Mutti · Canonical links verified through October 18, 2026

  1. CheckMate 743 TrialTreatment
  2. Mesothelioma BiomarkersDiagnosis
  3. Mesothelioma ChemotherapyTreatment
  4. Mesothelioma Cell Types
  5. Pleural Mesothelioma
  6. Pleurectomy and DecorticationSurgery
  7. Mesothelioma PrognosisPrognosis
  8. Heated Chemotherapy (HITHOC and HIPEC)Treatment
  9. Mesothelioma
  10. Peritoneal Mesothelioma
  11. Mesothelioma in Women
  12. PET CT Scan for MesotheliomaDiagnosis
  13. Mesothelioma SymptomsSymptoms
  14. Mesothelioma DiagnosisDiagnosis
  15. Understanding Your DiagnosisDiagnosis
  16. Mesothelioma TreatmentTreatment
  17. Mesothelioma SurgerySurgery
  18. Mesothelioma ImmunotherapyImmunotherapy
  19. Epithelioid Mesothelioma
  20. Testicular Mesothelioma
  21. Pericardial Mesothelioma

This appendix includes direct medical reviews only. Authorized bylines without direct review are not included.

08

Plain-language profile

Frequently asked questions

Who is Luciano Mutti?

Luciano Mutti is a physician-scientist and oncologist whose work has focused on malignant mesothelioma for more than 30 years. 1

What is Luciano Mutti known for?

Luciano Mutti is known for malignant mesothelioma research that connects clinical oncology with translational studies of tumor biology, biomarkers, treatment response and clinical evidence.

What is Luciano Mutti’s role with WikiMesothelioma?

Since August 2026, Luciano Mutti has served as a compensated independent medical reviewer for WikiMesothelioma.

What does medical review involve?

Luciano Mutti reviews selected WikiMesothelioma articles for medical accuracy and clarity.

Where can I read Luciano Mutti’s published research?

Luciano Mutti’s published research can be explored through his Google Scholar profile.

Career measures

30+
Years in mesothelioma research
Bench ↔ bedside
Translational focus
Medical review
Independent clinical scrutiny
Italy
Ireland
England · US
A career across four countries

Rome, Italy

Science,in service

Read Dr. Mutti’s published research and follow the development of his work.

Explore Google Scholar

Contact

Dr. Mutti serves WikiMesothelioma as a compensated independent medical reviewer and contractor, not as a staff member. Medical review does not imply endorsement of legal services.

The content on this site is for informational and educational purposes only and is not a substitute for professional medical advice.